Bausch + Lomb Corporation

Latest Results (18.11.2025):

Bausch + Lomb Corporation reported its Second-Quarter 2025 financial results, marking a period of steady revenue growth and strategic operational improvements. In this quarter, the company generated $1.278 billion in revenue with a GAAP net loss of $62 million attributable to the corporation. Adjusted EBITDA reached $191 million (with $192 million when excluding acquired IPR&D) and revenue increased 5% as reported (3% on a constant currency basis) compared to Q2 2024. The company also raised its full-year 2025 guidance, reflecting solid business performance and favorable foreign exchange tailwinds.

Financial Performance

Bausch + Lomb's Q2 2025 results included a revenue of $1.278 billion, a GAAP net loss of $62 million, and adjusted EBITDA of $191 million. The overall revenue grew 5% as reported (3% on a constant currency basis) compared to the corresponding quarter of 2024.

Segment Highlights

The Vision Care segment led growth with reported increases of 8% (6% at constant currency), while the Surgical segment grew by 3% (1% at constant currency). The Pharmaceuticals segment remained relatively flat, reflecting varied dynamics across product lines.

Guidance & Outlook

With a robust mix of hero products and a steady stream of new introductions, Bausch + Lomb raised its full-year 2025 guidance. The updated outlook takes into account both solid business performance and positive impacts from foreign exchange, setting the stage for future growth.

Operational & Strategic Initiatives

The quarter saw several strategic advancements: the company resumed full production of all enVista® platform IOLs following a voluntary recall, hit approximately $1 billion in trailing 12-month revenue for its dry eye portfolio, and successfully executed a refinancing transaction to extend its maturity profile, underscoring its commitment to maintaining operational resilience.